AzTrials
AzTrials

StrokeNCT00721357

Skeletal Muscle Properties and the Metabolic Cost of Walking Post-stroke

An observational study of Stroke, run by VA Office of Research and Development at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Of the ~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. Read more about this study

Who is it for?
Ages 18 to 80 yearsHealthy volunteers can take part
Conditions the study is for
Stroke
What is being tested?
Treadmill walking and Magnetic resonance spectroscopy
How many people
30 participants
Where
1 siteUnited States
Study dates
Aug 2008to Sep 2013
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: community sample

Who may be able to join

  • age 18-80;
  • stroke within past 6 months - 5 years;
  • residual paresis in the lower extremity (LE) (Fugl-Meyer motor score <34);
  • ability to sit unsupported for 30 sec;
  • ability to walk at least 10 ft with maximum 1 person assist;
  • self selected 10 meter gait speed < 0.8 m/s; and
  • provision of informed consent.

Who cannot join

  • Unable to ambulate at least 150 feet prior to stroke, or experienced intermittent claudication while walking < 200 meters;
  • history of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living;
  • History of chronic obstructive pulmonary disease or oxygen dependence;
  • Preexisting neurological disorders, dementia or previous stroke;
  • History of major head trauma;
  • Legal blindness or severe visual impairment;
Show all 15Show fewer
  • history of significant psychiatric illness;
  • Life expectancy <1 yr;
  • Severe arthritis or orthopedic problems that limit passive range of motion (ROM);
  • post-stroke depression (PHQ-9 10);
  • History of deep vein thrombosis (DVT) or pulmonary embolism within 6 months;
  • Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions;
  • Severe hypertension with systolic >200 mmHg and diastolic >110 mmHg at rest;
  • Previous or current enrollment in a clinical trial to enhance motor recovery;
  • Presence of non-magnetic resonance (MR) compatible implants or devices, pregnancy or severe claustrophobia.

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Ralph H. Johnson VA Medical Center, Charleston, SC

    Charleston, South Carolina, 29401-5799

Other trials in United States

About this study

Official title: Skeletal Muscle Properties and the Metabolic Cost of Walking Post-Stroke

Of the ~700,000 persons who suffer a stroke each year, only 50% recover the ability to perform unlimited community walking. One mechanism contributing to locomotor dysfunction post-stroke is an increased metabolic cost of walking relative to neurologically healthy individuals 2-4. This increased cost likely limits the amount of walking performed, which further reduces functional capacity, thus contributing to long-term spiral of disability and decreased quality of life in these persons. In addition to increased metabolic cost, increased estimates of mechanical work are also characteristic of hemiparetic walking 2,29. Interestingly, although estimates of mechanical work reflect work done by locomotor muscles, little is known about the impact that peripheral muscle properties have on estimates of mechanical work. Furthermore, questions concerning how these properties relate to the increased metabolic cost of walking remain unanswered. The short-term objective and purpose of the proposed research is to determine the extent to which peripheral muscle characteristics, as well as estimates of muscle mechanical energy expenditure (MMEE), relate to the metabolic cost of walking post-stroke.

Read the detailed description

A guiding principle of the proposed research is that skeletal muscle is the building block of all movement and, as such, muscle dysfunction can ultimately limit the gains possible from rehabilitation intervention. Therefore, maximal gains will be made only when central nervous system adaptations access peripheral muscle that is fully capable of supporting the increased activity.

The primary hypothesis is that in persons with hemiparesis following stroke, alterations in the metabolic properties of peripheral skeletal muscles, in combination with greater mechanical work, contribute to the increased metabolic cost of walking. A secondary hypothesis is that locomotor training induces adaptations in lower extremity skeletal muscle resulting in improved mechanical and metabolic efficiency. In order to test these hypotheses, the following three specific aims will be addressed:

Aim 1: Determine the in-vivo metabolic characteristics of the ankle plantar flexor muscles in persons with chronic post-stroke hemiparesis and neurologically healthy individuals. In-vivo muscle metabolic properties will be assessed via phosphorous magnetic resonance spectroscopy (31P-MRS). Specifically, we will measure the resting phosphorylation potential as well as the in-vivo oxidative capacity of the ankle plantar flexor muscles. We hypothesize that individuals with chronic hemiparesis will exhibit reductions in oxidative capacity as well as an increased resting phosphorylation potential relative to age-, gender-, height- and weight-matched control subjects. We suggest these adaptations, which are characteristic of a less energetically efficient muscle, contribute to an increased metabolic cost beyond that resulting from potential increases in mechanical work performed by locomotor muscles.

Aim 2: Quantify metabolic cost as well as muscle mechanical energy expenditure during walking in persons with chronic post-stroke hemiparesis and neurologically healthy individuals. Post-stroke hemiparesis is associated with a variety of motor control problems that include abnormal synergistic organization of movement as well as altered temporal sequencing of muscle activity 5,10,11. Since muscle excitation during normal walking is believed to be very efficient 8,9,33 it is likely that altered muscle coordination post-stroke, reflected in increased mechanical work, is one factor contributing to the increased metabolic cost of walking. We hypothesize that the metabolic cost of walking post-stroke will be elevated relative to controls at matched speeds. Additionally, a measure of mechanical work, muscle mechanical energy expenditure (MMEE), will be elevated post-stroke, reflective of mechanically inefficient movement strategies and causal to a portion of the increased metabolic cost of walking.

Aim 3: Determine the impact of 12 weeks of locomotor training on in-vivo muscle metabolic properties, the metabolic cost of walking as well as MMEE in persons with chronic post-stroke hemiparesis. There is emerging evidence that chronic neurologic deficits due to stroke can be improved through intensive, repetitive task-oriented motor training (e.g. locomotor training). The basis for locomotor training (LT) improvements is thought to involve mechanisms of central neuroplasticity that are responsive to fundamental principles of motor learning 37,38,39. In addition, our pilot data demonstrate that LT may also result in peripheral adaptations in the plantar flexor muscles. Thus, the potential seemingly exists to induce both central and peripheral adaptations with this intervention strategy. We expect that LT will attenuate existing deficits, resulting in an increased oxidative capacity and a decreased resting phosphorylation potential in ankle plantar flexor muscles. In addition, LT will result in a reduced MMEE and a reduced metabolic cost of walking, reflective of improved mechanical and metabolic efficiency. We believe it will prove important to describe adaptations in walking mechanics as well as within peripheral muscle that occur following LT and relate them to the metabolic cost of walking. In addition, continued deficits will reflect a need for additional or adjunctive intervention strategies, thus providing information on how to modify or augment future rehabilitation interventions in order to improve individual outcomes.

Conditions
Stroke
Being tested
Treadmill walking, Magnetic resonance spectroscopy
Keywords
muscles, work, Magnetic Resonance Imaging, control groups
Medical subject headings
Stroke

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Treadmill walkingBehavioural

    Subjects will perform treadmill walking at a self-selected velocity

  • Magnetic resonance spectroscopyOther

    Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)

Study groups in NCT00721357
Study groupRoleWhat they receive
StrokeStroke subjects
Receives: Behavioral: Treadmill walking; Other: Magnetic resonance spectroscopy
Controlneurologically healthy subjects
Receives: Behavioral: Treadmill walking; Other: Magnetic resonance spectroscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Oxygen Consumption During Walking

    Amount of oxygen consumed during walking at self-selected speed normalized to speed

    Measured: within one week of enrollment

Secondary outcomes (2)
  1. Muscle Mechanical Energy Expenditure

    mechanical work done by lower extremity joints

    Measured: one time measure within one week of enrollment

  2. Magnetic Resonance Spectroscopy of Muscle Metabolic Properties

    time constant indicating the time for recovery in muscle phosphocreatine levels following exercise as a metric of muscle oxidative capacity.

    Measured: within one week of enrollment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Jul 2008 (estimated)
  2. Study startAug 2008
  3. Primary completionJul 2012
  4. Study completionSep 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Cross-sectional
Enrolment
30 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00721357
Sponsor's protocol ID
B6341-W
Status last verified
Dec 2018
First submitted
21 Jul 2008
Last updated
18 Mar 2019
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

An observational study of Stroke, run by VA Office of Research and Development at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 15 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Mar 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 30 Jul 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Oxygen Consumption During Walking (time frame: within one week of enrollment). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Mar 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in